Median of mean age (years)
|
25.6
|
26
|
26
|
23.4
|
19.9
|
20.8
|
–
|
22.1
|
33
|
% missing data for mean age
|
55
|
80
|
64
|
38
|
41
|
71
|
93
|
60
|
57
|
Median of median age (years)
|
16.4
|
24
|
25
|
23
|
23.8
|
–
|
–
|
–
|
–
|
% missing data for median age
|
93
|
96
|
85
|
88
|
91
|
94
|
100
|
100
|
100
|
Age range (years)
|
0.3–90
|
0.4–88
|
0.2–75
|
6–65
|
0.25–84
|
1–74
|
12–62
|
0.8–65
|
16–74
|
Total number of males
|
2571
|
5137
|
5226
|
4522
|
684
|
1052
|
723
|
287
|
373
|
Total number of females
|
1141
|
1848
|
4233
|
2682
|
256
|
422
|
377
|
519
|
118
|
% (number) trials including healthy participants
|
14 (7)
|
22 (10)
|
28 (11)
|
29 (7)
|
18 (4)
|
35 (6)
|
14 (2)
|
40 (4)
|
71 (5)
|
% (number) trials including P. falciparum infection
|
88 (45)
|
78 (35)
|
72 (28)
|
71 (17)
|
77 (17)
|
41 (7)
|
86 (12)
|
60
|
14 (1)
|
% (number) trials including P. vivax infection
|
4 (2)
|
0 (0)
|
5 (2)
|
17 (4)
|
14 (3)
|
29 (5)
|
7 (1)
|
0 (0)
|
14 (1)
|
% (number) trials including uncomplicated malariainfection
|
45 (23)
|
69 (31)
|
72 (28)
|
71 (17)
|
77 (17)
|
35 (6)
|
71 (10)
|
60 (6)
|
29 (2)
|
% (number) trials including complicated or severe malaria infection
|
51 (26)
|
4 (2) (both studies also trialled quinine)
|
0 (0)
|
0 (0)
|
0 (0)
|
12 (2) (1 study just chloroquine, the other also trialled quinine)
|
0 (0)
|
0 (0)
|
0 (0)
|
% (number) trials excluding any medical comorbidities
|
31 (16)
|
58 (26)
|
62 (24)
|
71 (17)
|
68 (15)
|
65 (11)
|
57 (8)
|
90 (9)
|
86 (6)
|
% (number) trials specifically excluding cardiovascular comorbidities
|
12 (6)
|
16 (7)
|
49 (19)
|
38 (9)
|
46 (10)
|
41 (7)
|
14 (2)
|
60 (6)
|
57 (4)
|
% (number) trials excluding any co-medication use
|
65 (33)
|
53 (24)
|
62 (24)
|
42 (10)
|
54 (12)
|
71 (12)
|
57 (8)
|
100 (10)
|
86 (6)
|
% (number) trials excluding co-medication with antimalarials
|
57 (29)
|
44 (20)
|
39 (15)
|
13 (3)
|
36 (8)
|
24 (4)
|
50 (7)
|
80 (8)
|
43 (3)
|
% (number) trials excluding drugs which interfere with cardiovascular system
|
6 (3)
|
2 (1)
|
23 (9)
|
13 (3)
|
18 (4)
|
12 (2)
|
0 (0)
|
30 (3)
|
0 (0)
|